{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:56:23Z","timestamp":1793336183939,"version":"4.5.0"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once\u2010weekly semaglutide vs. dulaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study using Optum's de\u2010identified Clinformatics Data Mart (Optum CDM) from 1 January 2007 through 30 September 2024. New initiators of semaglutide or dulaglutide \u226518\u2009years with both T2D and ASCVD were included. The index date was the first date of a prescription claim for semaglutide or dulaglutide within the index medication identification period (1 January 2018 through 31 March 2024). The primary outcome was 3\u2010point MACE (stroke, myocardial infarction [MI], cardiovascular [CV]\u2010related death). Entropy balancing was applied to balance baseline characteristics. Weighted incidence rates per 1000 person\u2010years and doubly robust Cox proportional hazard ratios were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 75\u2009243 enrolees included (semaglutide, 42\u2009007; dulaglutide, 33\u2009236). The mean age was 68.2 and 69.3\u2009years (unweighted) in the semaglutide and dulaglutide cohorts, respectively. After balancing, standardized mean differences were &lt;0.1 for all variables. The incidence rates of the primary outcome, 3\u2010point MACE, were 25.7 and 33.0 in the semaglutide and dulaglutide cohorts, respectively. Compared with the dulaglutide cohort, the semaglutide cohort had a 22% lower risk of 3\u2010point MACE (hazard ratio, 0.78 [95% CI, 0.70\u20130.87];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among United States Medicare Optum CDM enrolees with T2D and ASCVD, semaglutide was associated with reduced risks of CV outcomes compared with dulaglutide. These results help to address an important evidence gap in selecting glucagon\u2010like peptide\u20101 receptor agonists for this high\u2010risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70440","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:12:12Z","timestamp":1767942732000},"page":"2661-2671","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of cardiovascular outcomes between once\u2010weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2409-5927","authenticated-orcid":false,"given":"Xi","family":"Tan","sequence":"first","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Liang","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Harton","sequence":"additional","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Genesis Research Group  Hoboken New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalak","family":"Muhammad","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Swift","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc.  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"de Havenon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Brain and Mind Health Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022194"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.05.002"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci23\u20100085"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S009"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.037"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31149\u20103"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010024\u201001678\u20104"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010025\u201006245\u2010w"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112473"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.048"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010018\u20100754\u2010z"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010021\u201001440\u20105"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/pan\/mpr025"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecosta.2023.11.004"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/por.S466505"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2577762"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.37297"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2792"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100922"},{"key":"e_1_2_11_22_1","unstructured":"KwanA SilvaR LiuM MaldonadoJ ChengA GreenJ.Efficacy and safety of tirzepatide in participants who achieved fasting serum glucose targets at 52\u2009weeks in SURPASS\u20103 and SURPASS\u20104. Podium presented at: European Association for the study of diabetes; 2024; Madrid Spain."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.09.007"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14443"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14160"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70440","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:22:54Z","timestamp":1773807774000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/dom.70440"],"URL":"https:\/\/doi.org\/10.1111\/dom.70440","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70440\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v1\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70440\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"2025-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}